RecruitingPhase 3NCT05100862
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Studying MALT lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BeiGene
- Principal Investigator
- Study DirectorBeiGene
- Intervention
- Zanubrutinib(drug)
- Enrollment
- 780 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2030
Study locations (30)
- Ucsf Fresno University of California San Francisco Fresno, Fresno, California, United States
- Kaiser Permanente Southern California, Irvine, California, United States
- Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
- Los Angeles Cancer Network, Los Angeles, California, United States
- Valkyrie Clinical Trials, Los Angeles, California, United States
- UCLA Hematologyoncology, Los Angeles, California, United States
- Scripps Health, San Diego, California, United States
- Sharp Healthcare Sharp Memorial Hospital, San Diego, California, United States
- Baptist Md Anderson Cancer Center, Jacksonville, Florida, United States
- Ascension Sacred Heart, Pensacola, Florida, United States
- Northwest Georgia Oncology Centers Marietta, Marietta, Georgia, United States
- Cancer Care Specialists of Illinois, Decatur, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
- Mission Cancer and Blood, Waukee, Iowa, United States
- Cotton Oneil Cancer Center, Topeka, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05100862 on ClinicalTrials.govOther trials for MALT lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07554898Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT LymphomaZhejiang Cancer Hospital
- RECRUITINGPHASE2NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaGottfried von Keudell, MD PhD
- RECRUITINGPHASE2NCT07441993Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07372365Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.The First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT06796998Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)Izidore Lossos, MD
- RECRUITINGNCT06712459Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone LymphomaInternational Extranodal Lymphoma Study Group (IELSG)
- ACTIVE NOT RECRUITINGPHASE2NCT07480863Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ACTIVE NOT RECRUITINGPHASE2NCT07247383Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University